OBJECTIVES: The objective of this research was to characterize type 2 diabetes (T2D) patients initiating semaglutide and tirzepatide and to describe subsequent weight loss and change in body mass index (BMI) in the real-world setting.

METHODS: Electronic health records from 6 integrated delivery networks within the OMNY Health real-world data platform from 2017 to 2024 were accessed. Patients were included if they ever had a diagnosis code for T2D, initiated semaglutide or tirzepatide, had an assessment of weight or BMI at treatment initiation, and had at least 1 follow-up assessment. Weight status at treatment initiation was categorized using BMI per international guidelines. Outcomes comprised absolute change in weight and change in weight status category and were evaluated at 3, 6, 9, and 12 months after treatment initiation.

RESULTS: Of over 1.5 million T2D patients, 148,687 had a prescription for either semaglutide or tirzepatide, 99,026 had a weight or BMI assessment at treatment initiation, and 13,053 (10,530 semaglutide, 2,523 tirzepatide) had at least 1 follow-up assessment that occurred at the 3-, 6-, 9-, and/or 12-month mark (+/- 1 month). Distributions of gender (60% female), race (23% nonwhite), and age (64% > 60 years) were similar between semaglutide and tirzepatide patients. At treatment initiation, 88% of patients were obese, and 11% were overweight. Mean weight loss (semaglutide/tirzepatide) from treatment initiation was 6.6 (5.9/8.8), 9.5 (8.0/15.5), 10.7 (9.4/18.3), and 11.2 (9.6/22.3) pounds at 3, 6, 9, and 12 months, respectively. The proportions of patients classified into a healthier weight class (semaglutide/tirzepatide) were 6% (5%/7%), 8% (8%/12%), 9% (8%/15%), and 9% (8%/16%) at 3, 6, 9, and 12 months, respectively.

CONCLUSIONS: Results provide a descriptive insight into the T2D patient experience in the real-world setting. Future analyses may include multivariable and/or propensity score analyses for formal treatment comparison.